Cost-effectiveness of treatment of women aged 70 years and older with both osteopenia and microstructural deterioration

Liew, Danny; Chapurlat, R. D.; Sornay-Rendu, E.; Lespessailles, Eric; Peng, Yu; Seeman, Ego

Affiliations

¹Dept Social and Preventative Medicine, Alfred Hospital, Monash University, Melbourne, Australia

²INSERM UMR 1033, Université de Lyon, Lyon 69437, France

³IPROS, Université d'Orléans, Orléans, France

⁴Straxcorp, 410 Collins St, Melbourne, Australia

⁵Dept Endocrinology and Medicine, Austin Health, University of Melbourne, Melbourne, Australia

Abstract and keywords

Objective: Treatment is usually withheld from women with osteopenia even though they are the source of over 70% of all women having fragility fractures. As microstructural deterioration increases fracture risk and zoledronate reduces it, we aimed to determine whether identifying and treating women with osteopenia and severe microstructural deterioration is cost-effective. We also compared the health economic outcomes of ‘global’ versus ‘targeted’ treatment using SFS of women aged ≥70 years with osteopenia.

Design: We assessed the cost-effectiveness from using a Markov model that simulated 10-year follow up of women with osteopenia. Decision analysis compared measurement of distal radial microstructure using high resolution peripheral computed tomography (at a cost of USD $210) to target women with severe microstructural deterioration for zoledronate treatment, compared to standard care defined as measurement of bone mineral density (BMD) with treatment recommended when femoral neck BMD T score is ≤−2.5 SD with or without a prevalent fracture. In the ‘global’ treatment approach, high resolution peripheral quantitative tomography (HRpQCT) was not undertaken.

Setting: US healthcare system.

Participants: A hypothetical cohort of 1000 women aged ≥70 years with osteopenia and no previous fractures was studied.

Measures: Fractures, deaths, years of life lived, quality-adjusted life years (QALYs) lived and costs. Data inputs were obtained from published sources. A 3% annual discount rate was applied to future health benefits and costs.

Results: Women in the standard care group incurred 327 fractures during 7341.0 years and 4914.2 QALYs lived. Women in the intervention group incurred 300 fractures (number needed to treat 37) during 7359.2 years and 4928.8 QALYs lived. Net costs were USD $4,862,669 and $4,952,004, respectively, equating to 18.1 years of life saved and 14.6 QALYs saved, and incremental cost-effectiveness ratios of $4992 per year of life saved and $6135 per QALY saved. These ratios are well within the threshold considered to be cost-effective. Sensitivity analyses indicated the results were robust.

Relative to standard of care, ‘global’ and ‘targeted’ treatment respectively resulted in 0.0364 vs. 0.0181 years of life (YoLS) saved per person, and 0.0292 and 0.0146 QALYs saved per person. The net costs per person for the respective approaches were $US 359 and $US 89. The incremental cost-effectiveness ratios were $9864 per YoLS and $12,290 per QALY saved for the ‘global’ approach and $4992 per YoLS and $6135 per QALY saved for the ‘targeted’ approach.

Conclusion: Identifying and treating women ≥70 years of age with osteopenia and microstructural deterioration with zoledronate cost-effectively reduces the morbidity and mortality imposed by fragility fractures. This ‘targeted’ approach is more cost-effective than a ‘global’ approach and incurs only 25% of total costs.

Implication: Women with osteopenia with bone fragility due to microstructural deterioration should be identified and targeted for treatment.

Summary: Women with osteopenia have 70% of fractures. Treating those with microstructural deterioration conferred an incremental cost-effectiveness ratio of $4992/year of life saved and $6135 per QALY saved.

Keywords: Bone mineral density; Cost effectiveness; Microstructural deterioration; Osteopenia; Osteoporosis; Screening; Treatment

Links

DOI: 10.1016/j.bone.2020.115682

PubMed: 33039577

WoS: 000601336400015

History

Received: 2020-05-22

Revised: 2020-10-5

Accepted: 2020-10-5

Online: 2020-10-9

Cited Works (16)

Year	Entry
2014	Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, Dawson‐Hughes B. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res. November 2014;29(11):2520-2526.
2009	Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB. Incidence and mortality of hip fractures in the United States. JAMA. October 14, 2009;302(10):1573-1579.
2014	Bala Y, Zebaze R, Ghasem-Zadeh A, Atkinson EJ, Iuliano S, Peterson JM, Amin S, Bjørnerem Å, Melton LJ III, Johansson H, Kanis JA, Khosla S, Seeman E. Cortical porosity identifies women with osteopenia at increased risk for forearm fractures. J Bone Miner Res. June 2014;29(6):1356-1362.
2017	Johansson H, Siggeirsdóttir K, Harvey NC, Odén A, Gudnason V, McCloskey E, Sigurdsson G, Kanis JA. Imminent risk of fracture after fracture. Osteoporos Int. March 2017;28(3):775-780.
2004	Siris ES, Chen Y-T, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE, Berger ML. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. May 24, 2004;164(10):1108-1112.
2011	Morin S, Lix LM, Azimaee M, Metge C, Caetano P, Leslie WD. Mortality rates after incident non-traumatic fractures in older men and women. Osteoporos Int. September 2011;22(9):2439-2448.
2002	Delmas PD. Treatment of postmenopausal osteoporosis. Lancet. June 8, 2002;359(9322):2018-2026.
1994	Kanis JA; WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporos Int. November 1994;4(6):368-381.
2018	Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Wong S, Wiessing KR, Bolland MJ, Bastin S, Gamble GD. Fracture prevention with zoledronate in older women with osteopenia. NEJM. December 20, 2018;379(25):2407-2416.
2013	Zebaze R, Ghasem-Zadeh A, Mbala A, Seeman E. A new method of segmentation of compact-appearing, transitional and trabecular compartments and quantification of cortical porosity from high resolution peripheral quantitative computed tomographic images. Bone. May 2013;54(1):8-20.
2009	Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C; FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. NEJM. August 20, 2009;361(8):756-765.
1988	Schaffler MB, Burr DB. Stiffness of compact bone: effects of porosity and density. J Biomech. 1988;21(1):13-16.
1998	Laib A, Häuselmann HJ, Rüegsegger P. In vivo high resolution 3D-QCT of the human forearm. Technol Health Care. 1998;6(5-6):329-337.
2007	Burge R, Dawson‐Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis‐related fractures in the United States, 2005–2025. J Bone Miner Res. March 2007;22(3):465-475.
1997	Arlot ME, Sornay-Rendu E, Garnero P, Vey-Marty B, Delmas PD. Apparent pre- and postmenopausal bone loss evaluated by DXA at different skeletal sites in women: the OFELY cohort. J Bone Miner Res. April 1997;12(4):683-690.
2006	Pasco JA, Seeman E, Henry MJ, Merriman EN, Nicholson GC, Kotowicz MA. The population burden of fractures originates in women with osteopenia, not osteoporosis. Osteoporos Int. September 2006;17(9):1404-1409.

Cited By (1)

Year	Entry
2021	Whittier DEW. The Assessment of Fragility Fracture Risk Using HR-PQCT as a Novel Tool for Diagnosis of Osteoporosis [PhD thesis]. Calgary, AB: University of Calgary; August 2021.